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Pharmacotherapy is an indicator of severity of hyperglycemia in pregnancy that may 
reflect β-cell dysfunction in women with gestational diabetes mellitus.  
Methods and Results 
 Life after gestational diabetes Ahvaz Study (LAGAs) is a population-based 
prospective cohort study to investigate potential short and long-term metabolic 
outcomes of gestational diabetes in mothers and their offsprings. Pregnant women 
attending 25 urban public and private centers seeking prenatal care were recruited 
from March 2015. 19.3% (34/176) of women with gestational diabetes required 
pharmacotherapy in pregnancy (12.5% insulin and 6.8% metformin). The mean age 
of women who needed pharmacotherapy was 31.0 (SD, 4.6) years vs 29.3 (SD, 5.3) 
years in diet-treated women. Cesarean delivery, higher FPG at first visit of 
pregnancy and premature delivery were significantly associatiated  with need to 
pharmacotherapy in pregnancy (p<0.05).   
Conclusions 
Although the use of oral anti-diabetic drugs in pregnancy is not recommended by the 
American diabetes Association (ADA), consumption of them in women exposed to 
gestational diabetes is considerable. Use of insulin or metformin for management of 
hyperglycemia in pregnancy strongly prognoses metabolic disturbance later in life.  
Therefore postpartum prevention and screening program for cardiovascular risk 
factors is important for women with GDM who required pharmacotherapy for 
management of hyperglycemia in pregnancy. 
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